BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19717459)

  • 1. Probing PML body function in ALT cells reveals spatiotemporal requirements for telomere recombination.
    Draskovic I; Arnoult N; Steiner V; Bacchetti S; Lomonte P; Londoño-Vallejo A
    Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15726-31. PubMed ID: 19717459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo assembly of a PML nuclear subcompartment occurs through multiple pathways and induces telomere elongation.
    Chung I; Leonhardt H; Rippe K
    J Cell Sci; 2011 Nov; 124(Pt 21):3603-18. PubMed ID: 22045732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PML induces compaction, TRF2 depletion and DNA damage signaling at telomeres and promotes their alternative lengthening.
    Osterwald S; Deeg KI; Chung I; Parisotto D; Wörz S; Rohr K; Erfle H; Rippe K
    J Cell Sci; 2015 May; 128(10):1887-900. PubMed ID: 25908860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere maintenance by telomerase and by recombination can coexist in human cells.
    Cerone MA; Londono-Vallejo JA; Bacchetti S
    Hum Mol Genet; 2001 Sep; 10(18):1945-52. PubMed ID: 11555631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference.
    Jiang WQ; Zhong ZH; Henson JD; Reddel RR
    Oncogene; 2007 Jul; 26(32):4635-47. PubMed ID: 17297460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of TRF2 in ALT cells causes PML-dependent p53 activation and loss of telomeric DNA.
    Stagno D'Alcontres M; Mendez-Bermudez A; Foxon JL; Royle NJ; Salomoni P
    J Cell Biol; 2007 Dec; 179(5):855-67. PubMed ID: 18056407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells.
    Yu J; Lan J; Wang C; Wu Q; Zhu Y; Lai X; Sun J; Jin C; Huang H
    Cancer Lett; 2010 May; 291(2):177-86. PubMed ID: 19900757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hRad21 overexpresses and localizes to the ALT-associated promyelocytic leukemia body in ALT cells.
    Zhao B; Wang ZJ; Yi BQ; Ma HC; Xu HM
    Cancer Biol Ther; 2010 Jun; 9(12):978-83. PubMed ID: 20364118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
    Grobelny JV; Kulp-McEliece M; Broccoli D
    Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.
    Slatter T; Gifford-Garner J; Wiles A; Tan X; Chen YJ; MacFarlane M; Sullivan M; Royds J; Hung N
    Am J Pathol; 2010 Dec; 177(6):2694-700. PubMed ID: 21037079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body.
    Yeager TR; Neumann AA; Englezou A; Huschtscha LI; Noble JR; Reddel RR
    Cancer Res; 1999 Sep; 59(17):4175-9. PubMed ID: 10485449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomere length heterogeneity in ALT cells is maintained by PML-dependent localization of the BTR complex to telomeres.
    Loe TK; Li JSZ; Zhang Y; Azeroglu B; Boddy MN; Denchi EL
    Genes Dev; 2020 May; 34(9-10):650-662. PubMed ID: 32217664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative lengthening of telomeres is a self-perpetuating process in ALT-associated PML bodies.
    Zhang JM; Genois MM; Ouyang J; Lan L; Zou L
    Mol Cell; 2021 Mar; 81(5):1027-1042.e4. PubMed ID: 33453166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.
    Shen H; Maki CG
    J Cell Biochem; 2010 Dec; 111(5):1280-90. PubMed ID: 20803550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies.
    Jeyapalan JN; Mendez-Bermudez A; Zaffaroni N; Dubrova YE; Royle NJ
    Int J Cancer; 2008 Jun; 122(11):2414-21. PubMed ID: 18311780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PML and TRF2 protein expression in hereditary and sporadic colon cancer.
    Plevová P; Bouchal J; Fiurásková M; Papezová M; Krepelová A; Curík R; Foretová L; Navrátilová M; Zapletalová J; Posolda T; Kolár Z
    Neoplasma; 2007; 54(4):269-77. PubMed ID: 17822315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of hRad9, hHus1, hRad1, and hRad17 and caffeine-sensitive DNA replication at the alternative lengthening of telomeres-associated promyelocytic leukemia body.
    Nabetani A; Yokoyama O; Ishikawa F
    J Biol Chem; 2004 Jun; 279(24):25849-57. PubMed ID: 15075340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomere recombination requires the MUS81 endonuclease.
    Zeng S; Xiang T; Pandita TK; Gonzalez-Suarez I; Gonzalo S; Harris CC; Yang Q
    Nat Cell Biol; 2009 May; 11(5):616-23. PubMed ID: 19363487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assembly of functional ALT-associated promyelocytic leukemia bodies requires Nijmegen Breakage Syndrome 1.
    Wu G; Jiang X; Lee WH; Chen PL
    Cancer Res; 2003 May; 63(10):2589-95. PubMed ID: 12750284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle.
    Grobelny JV; Godwin AK; Broccoli D
    J Cell Sci; 2000 Dec; 113 Pt 24():4577-85. PubMed ID: 11082050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.